Condition: Hip Fracture · Anemia · Sponsor: Soren Overgaard
The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture The main questions it aims to answer are: It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration. The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score. Participants will: \- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery. This trial will be conducted at three hospitals in Denmark, involving an anticipated 210 participants.
This description comes directly from the study's public registry record.
Nicolas Tekin Jones, MD · +4520491890 · nicolas.tekin.jones@regionh.dk
Søren Overgaard, MD, DMSc · soeren.overgaard@regionh.dk
Always discuss trial participation with your own doctor first.
| Department of Orthopedic Surgery and Traumatology, Bispebjerg, Copenhagen University Hospital | Copenhagen NV, Denmark | Active Not Recruiting |
| Department of Orthopedic Surgery and Traumatology, Herlev, Copenhagen University Hospital | Herlev, Denmark | Recruiting |
| Department of Orthopaedic Surgery, Odense and Svendborg University Hospital | Odense C, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06898814